The fluorescent probes could conceivably be used to monitor cathepsins and other proteases implicated in neurodegenerative disorders such as Alzheimer disease, suggested Bogyo in an interview with ARF, though he cautioned that the blood-brain barrier, a familiar hurdle to neuroscientists, might be the major obstacle to using these molecules for direct brain imaging.